ArticleBMC biotechnology2025
An anti-idiotypic single domain antibody as Cry2Aa toxin mimotope and analysis of its binding region through molecular docking.
Article in BMC biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundAnti-idiotypic antibodies have garnered significant attention in biotechnology and immunology due to their unique ability to mimic specific epitopes on target antigens, thereby serving as functional analogues. This property makes them valuable tools for various applications. In this study, we aimed to isolate an anti-idiotypic single domain antibody against Cry2Aa from a naive phage-display library and investigate its structural and functional mimicry of the Cry2Aa toxin.
resultsAn anti-idiotypic single domain antibody (sdAb) specific for the Cry2Aa toxin was successfully isolated from a naive phage-display library. Sequence analysis revealed a 57.1% identity between the epitopes on Cry2Aa mimicked by the sdAb and Cry2Aa. The sdAb could compete with Cry2Aa toxin for binding to anti-Cry2Aa F(ab')
conclusionsThe findings from this study indicate that the isolated Cry2Aa anti-idiotypic sdAb mimics the molecular interaction pattern of the Cry2Aa toxin with its midgut receptors. The anti-idiotypic sdAb offers new potential for developing novel insect control strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.